Profile data is unavailable for this security.
About the company
genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.
- Revenue in GBP (TTM)272.00k
- Net income in GBP-5.00m
- Incorporated2007
- Employees43.00
- LocationGenedrive PLC48 Grafton StreetMANCHESTER M13 9XXUnited KingdomGBR
- Phone+44 161 989 0245
- Fax+44 161 989 0262
- Websitehttp://www.genedriveplc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Myhealthchecked PLC | 10.98m | -159.00k | 5.20m | 10.00 | -- | 0.5975 | 81.26 | 0.4738 | -0.0031 | -0.0031 | 0.2111 | 0.1674 | 0.8863 | 10.98 | 4.44 | 1,097,700.00 | -1.28 | -7.24 | -1.81 | -10.39 | 18.66 | 22.82 | -1.45 | -5.13 | 2.46 | -- | 0.003 | -- | -50.81 | 368.95 | -110.48 | -- | -2.00 | -- |
Rua Life Sciences PLC | 1.87m | -1.87m | 6.83m | 40.00 | -- | 0.6535 | -- | 3.65 | -0.0843 | -0.0843 | 0.0843 | 0.1683 | 0.3293 | 3.26 | 4.80 | 46,725.00 | -32.95 | -25.97 | -36.33 | -28.26 | 81.97 | -- | -100.05 | -110.53 | 2.40 | -61.71 | 0.1065 | -- | 34.09 | 40.08 | 3.10 | -- | 94.82 | -- |
Cambridge Nutritional Sciences PLC | 9.05m | -3.21m | 8.45m | 91.00 | -- | 0.908 | -- | 0.9338 | -0.0136 | -0.0105 | 0.0385 | 0.0391 | 0.5857 | 3.97 | 2.05 | 99,406.59 | -20.81 | -10.49 | -23.88 | -11.90 | 52.90 | 59.24 | -35.53 | -27.40 | 4.22 | -128.47 | 0.0225 | -- | -11.63 | -1.96 | -125.12 | -- | -45.83 | -- |
Genedrive PLC | 272.00k | -5.00m | 9.10m | 43.00 | -- | 1.70 | -- | 33.45 | -0.0407 | -0.0407 | 0.0022 | 0.0098 | 0.0658 | -- | 1.60 | 6,325.58 | -120.84 | -97.55 | -197.86 | -128.51 | -- | -- | -1,837.50 | -797.03 | 1.36 | -7.49 | 0.0789 | -- | 12.24 | -50.95 | -10.16 | -- | 16.72 | -- |
Feedback plc | 886.00k | -3.49m | 9.13m | 24.00 | -- | 1.02 | -- | 10.31 | -0.2614 | -0.2614 | 0.0664 | 0.6726 | 0.0774 | -- | 3.74 | 36,916.67 | -30.44 | -28.58 | -32.67 | -31.74 | 90.60 | 92.61 | -393.47 | -299.13 | -- | -- | 0.00 | -- | 74.15 | 17.46 | -37.74 | -- | 56.22 | -- |
Proteome Sciences plc | 5.03m | -2.44m | 11.07m | 35.00 | -- | -- | -- | 2.20 | -0.0083 | -0.0083 | 0.017 | -0.0104 | 0.4209 | 3.89 | 3.04 | 143,657.10 | -20.45 | -1.22 | -- | -- | 32.76 | 54.53 | -48.59 | -2.20 | 0.2667 | -2.03 | 1.29 | -- | -35.37 | 10.52 | -284.38 | -- | 126.22 | -- |
Inspiration Healthcare Group PLC | 37.63m | -6.32m | 11.94m | 210.00 | -- | 0.4122 | -- | 0.3173 | -0.0925 | -0.0925 | 0.5516 | 0.4245 | 0.7243 | 1.67 | 3.66 | -- | -12.17 | 0.8965 | -14.86 | 1.10 | 47.53 | 47.61 | -16.80 | 0.9922 | 0.9698 | -0.9172 | 0.307 | -- | -8.74 | 19.43 | -2,423.90 | -- | 31.88 | -- |
Genincode PLC | 2.16m | -7.02m | 11.95m | 36.00 | -- | 5.02 | -- | 5.53 | -0.0732 | -0.0732 | 0.0225 | 0.0135 | 0.2703 | 21.88 | 3.33 | 60,000.00 | -87.79 | -- | -124.10 | -- | 47.31 | -- | -324.81 | -- | 1.24 | -- | 0.1883 | -- | 51.05 | -- | -26.21 | -- | -- | -- |
Abingdon Health PLC | 5.34m | -2.24m | 12.99m | 82.00 | -- | 6.88 | -- | 2.43 | -0.0184 | -0.0184 | 0.0439 | 0.0149 | 0.8978 | 7.67 | 4.74 | 65,170.73 | -37.55 | -51.31 | -58.04 | -79.85 | 57.35 | 33.16 | -41.82 | -139.64 | 1.59 | -- | 0.3572 | -- | 42.68 | -- | 83.77 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Peel Hunt LLPas of 24 Jun 2024 | 54.27m | 17.58% |
Hargreaves Lansdown Asset Management Ltd.as of 01 Jan 2022 | 5.48m | 1.78% |
Jarvis Investment Management Ltd.as of 14 Jun 2023 | 2.95m | 0.96% |
IG Markets Ltd.as of 01 Jan 2022 | 2.74m | 0.89% |
Rathbones Investment Management Ltd.as of 01 Jan 2022 | 2.35m | 0.76% |
HSBC Global Asset Management (UK) Ltd.as of 01 Jan 2022 | 2.21m | 0.71% |
BGF Investment Management Ltd.as of 05 Feb 2021 | 1.91m | 0.62% |
Walker Crips Investment Management Ltd.as of 01 Jan 2022 | 1.90m | 0.61% |
M&G Investment Management Ltd.as of 05 Feb 2020 | 1.76m | 0.57% |
Unicorn Asset Management Ltd.as of 31 May 2024 | 1.15m | 0.37% |